Discontinuation of Antihyperlipidemic Drugs – Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?

New England Journal of Medicine

Volumn 332, Issue 17, 1995, Pages 1125-1131

  Andrade, Susan E ^a   Walker, Alexander M ^a   Gottlieb, Lawrence K ^a   Hollenberg, Norman K ^a   Testa, Marcia A ^a   Saperia, Gordon M ^a   Platt, Richard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID; COLESTYRAMINE; GEMFIBROZIL; LIPID; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTILIPEMIC AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0028967825     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199504273321703     Document Type: Article

References (46)

1. Clofibrate and niacin in coronary heart disease JAMA 1975; 231: 360-381
2. Frick MH, Elo O, Haapa K, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-1245
3. Bradford RH, Shear CL, Chremos AN, Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-49
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364
5. The Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118
6. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
7. Betteridge DJ, Bhatnager D, Bing RF, Treatment of familial hypercholesterolemia: United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992; 304: 1335-1338
8. Gotto AM Jr, Breen WJ, Corder CN, Once-daily, extended-release gemfibrozil in patients with dyslipidemia: the Lopid SR Work Group I. Am J Cardiol 1993; 71: 1057-1063
9. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB Colestipol hydrochloride in hypercholesterolemic patients -- effect on serum cholesterol and mortality. J Chronic Dis 1978; 31: 5-14
10. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantell G Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia: the Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther 1992; 14: 708-717
11. Bates MC, Warren SG, Grubb S, Chillag S Effectiveness of low-dose lovastatin in lowering serum cholesterol: experience with 56 patients. Arch Intern Med 1990; 150: 1947-1950
12. Blankenhorn DH, Azen SP, Kramsch DM, Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969-976
13. Brensike JF, Levy RI, Kelsey SF, Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313-324
14. Cooper EE, Michel AM Colestipol hydrochloride, a new hypolipidemic drug: a two-year study. South Med J 1975; 68: 303-309
15. Crepaldi G, Baggio G, Arca M, Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia: the Italian Multicenter Pravastatin Study I. Arch Intern Med 1991; 151: 146-152
16. Eisalo A, Manninen V A long-term trial of gemfibrozil in the treatment of hyperlipidaemias. Proc R Soc Med 1976; 69: Suppl 2: 49-52
17. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki Heart Study frame population. Ann Med 1993; 25: 41-45
18. Goldberg R, LaBelle P, Zupkis R, Ronca P Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990; 66: 16B-21B
19. Itskovitz HD, Flamenbaum W, DeGaetano C, Pritchard KA Jr, Stemerman MB Effect of lovastatin on serum lipids in patients with nonfamilial primary hypercholesterolemia. Clin Ther 1989; 11: 862-872
20. Kannel WB, D'Agostino RB, Stepanians M, D'Agostino LC Efficacy and tolerability of lovastatin in a six-month study: analysis by gender, age and hypertensive status. Am J Cardiol 1990; 66: 1B-10B
21. Knopp RH, Ginsberg J, Albers JJ, Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 642-650
22. Koskinen P, Kovanen PT, Tuomilehto J, Manninen V Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers. Arch Intern Med 1992; 152: 90-96
23. Kundu SC, Roxy S, Batabyal SK Gemfibrozil in dyslipidaemia. J Assoc Physicians India 1990; 38: 156-159
24. Luria MH Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 1988; 148: 2493-2495
25. Olsson AG, Rossner S, Walldius G, Carlson LA Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Proc R Soc Med 1976; 69: Suppl 2: 29-31
26. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia: Pravastatin Multicenter Study Group II. Arch Intern Med 1993; 153: 1321-1329
27. Ryan JR, Jain AK, McMahon FG Long-term treatment of hypercholesterolemia with colestipol hydrochloride. Clin Pharmacol Ther 1975; 17: 83-87
28. Sahni R, Maniet AR, Voci G, Banka VS Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121: 1600-1608
29. Varthakavi PK, Turakhia DP, Sharma SS, Salgaonkar DS, Nihalani KD, Joshi VR Gemfibrozil in hyperlipidaemia: an open, single blind trial. J Assoc Physicians India 1990; 38: 136-140
30. Watts GF, Lewis B, Brunt JNH, Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569
31. Yovos JG, Patel ST, Falko JM, Newman HAI, Hill DS Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. J Clin Endocrinol Metab 1982; 54: 1210-1215
32. Thurmer HL, Lund-Larsen PG, Tverdal A Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens 1994; 12: 481-490
33. Haynes RB, Sackett DL, Gibson ES, Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1: 1265-1268
34. Gallup G Jr, Cotugno HE Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med 1986; 81: Suppl 6C: 20-24
35. Inui TS, Carter WB, Pecoraro RE, Pearlman RA, Dohan JJ Variations in patient compliance with common long-term drugs. Med Care 1980; 18: 986-993
36. German PS Compliance and chronic disease. Hypertension 1988; 11: Suppl 2: II-56
37. MRC trial of treatment of mild hypertension: principal results: Medical Research Council Working Party. BMJ 1985; 291: 97-104
38. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253: 3263-3268
39. Caldwell JR, Cobb S, Dowling MD, de Jongh D The dropout problem in antihypertensive treatment: a pilot study of social and emotional factors influencing a patient's ability to follow antihypertensive treatment. J Chronic Dis 1970; 22: 579-592
40. Gillum RF, Neutra RR, Stason WB, Solomon HS Determinants of dropout rate among hypertensive patients in an urban clinic. J Community Health 1979; 5: 94-100
41. Engelland AL, Alderman MH, Powell HB Blood pressure control in private practice: a case report. Am J Public Health 1979; 69: 25-29
42. Schectman G, Hiatt J, Hartz A Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol 1993; 71: 759-765
43. Wirebaugh SR, Whitney EJ Compliance of four lipid lowering agents at one year in a preventive cardiology clinic. Pharmacotherapy 1992; 12: 263-263 abstract.
44. Wirebaugh SR, Whitney EJ Long-term compliance with lipid-lowering therapy. Pharmacol Ther 1993; 18: 559-571
45. Oster G, Epstein AM Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987; 258: 2381-2387
46. Schulman KA, Kinosian B, Jacobson TA, Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990; 264: 3025-3033